Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01011)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that, based on the information currently available to the Group, the Group is expected to record a profit for the six months ending 30 June 2019 (the "**Period Under Review**"). As compared with the year ended 31 December 2018, the Group may successfully turn loss into profit. However, as compared to the corresponding period in 2018, the profitability may decline substantially.

This announcement is made by China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the information currently available to the Group, the board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that the Group is expected to record a profit for the Period Under Review but the profit may be substantially lower than that for the corresponding period in 2018. The reduced profitability is mainly due to the decrease in operating income as a result of the external policies faced by the Group and the continuing challenging business environment, as well as the increase in business development costs and operating expenses for the Period under Review. The Group endeavors to enhance the profitability for the whole year of 2019 by continually improving its business performance in the second half of the year.

The announcement is made solely based on the preliminary assessment of the Board after reviewing the estimated financial results of the Group and the information currently available to the Group, which is still in the process of being finalised and which has not been reviewed by the Company's auditors. Further details of the Company's financial performance will be provided in the announcement for the interim results of the Group for the Period Under Review, which is expected to be published before the end of August 2019.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 24 June 2019

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu, Mr. Wu Weizhong and Mr. Wang Fei; the non-executive Directors are Dr. Qian Wei and Ms. Lou Jianying; and the independent non-executive Directors are Mr. Patrick Sun, Dr. Hong Yan and Mr. Yu Tze Shan Hailson.